You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥-B(06996.HK):與翰森製藥就希維奧®(塞利尼索)在中國大陸的商業化合作達成協議

格隆匯8月11日丨德琪醫藥-B(06996.HK)發佈公吿,德琪醫藥的附屬公司Antengene Corporation (Hong Kong) Limited及德琪(浙江)醫藥科技有限公司與翰森製藥集團有限公司(“翰森製藥”)的全資附屬公司江蘇豪森藥業集團有限公司就希維®(塞利尼索)在中國大陸的商業化訂立獨家合作協議。

希維奧®(塞利尼索)聯合地塞米松已於2021年12月14日在中國大陸獲批用於治療復發╱難治性多發性骨髓瘤,並於2022年5月實現商業化上市。協議達成的目的是為了通過翰森製藥目前的商業組織架構擴大希維奧®(塞利尼索)的覆蓋範圍及提高中國大陸病者用藥的可及性。

根據協議條款,德琪醫藥將繼續負責希維奧®(塞利尼索)的研發、監管審批事務、產品供應和分銷,而翰森製藥將獨家負責希維奧®(塞利尼索)在中國大陸的商業化。德琪醫藥將從翰森製藥獲得最高可達人民幣2億元的首付款,其中人民幣1億元於簽訂協議時支付,並根據協議及其條款和條件,德琪醫藥將有權從翰森製藥獲得最高可達人民幣1億元的剩餘首付款,以及最高可達人民幣5.35億元的里程碑付款。德琪醫藥將繼續就中國大陸的希維奧® (塞利尼索)錄得收入,而翰森製藥將從德琪醫藥收取服務費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account